A new scientific review co-authored by CoEHAR researchers explores the role of finerenone, a medication used to protect the heart and kidneys in high-risk patients with diabetes and chronic kidney…
Smoking remains one of the most important — and most neglected — modifiable risk factors in the management of type 2 diabetes (T2D). Despite strong evidence that quitting reduces cardiovascular…
CoEHAR is proud to announce that Dr. Rossella Cannarella has been awarded one of the prestigious Tobacco Harm Reduction Scholarships (THRSP) — an international program supporting early-career researchers engaged in…
For people living with diabetes, smoking represents much more than a harmful habit — it is a major driver of cardiovascular complications and long-term metabolic damage. Quitting is one of…
For two days, on November 10 and 11, Catania became the world capital of research on diabetes and smoking. At the Plaza Hotel, the first Delphi Consensus Meeting of the…
Following the success of the first edition held in May 2025, the University of Catania and CoEHAR – Center of Excellence for the Acceleration of Harm Reduction – together with…
On May 30–31, 2025, the international scientific conference “TYPE 2 Diabetes in Internal Medicine Practice: Experience Sharings 1” was held in Catania, at the Romano Palace Hotel, bringing together over…
The University of Catania is proud to announce the upcoming international scientific conference titled "TYPE 2 Diabetes in Internal Medicine Practice: Experience Sharings 1", which will take place on May 30-31, 2025,…
On Saturday 16th November, Prof. Riccardo Polosa joined the 2024 Annual Cardiorenal, Obesity & Metabolic Health Summit held in Fujairah (UAE) to deliver an oral presentation on diabetes, smoking cessation…
Researchers from the CoEHAR at the University of Catania, together with international experts from the DiaSmokeFree Working Group, aimed to answer these questions: what could be the effects of smoking cessation on the efficacy and safety of antidiabetic drugs? Could significant changes occur that would require a readjustment of pharmacological treatments?
